Patent application number | Description | Published |
20090068635 | INDIRECTLY LABELLED ASSAY CONJUGATES AND METHODS OF PREPARING AND USING SAME - Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided. | 03-12-2009 |
20090111123 | COMPOSITIONS FOR DETECTING ANTIBODIES TO BABESIA MICROTI AND METHODS OF USES THEREOF - The present invention relates to one or more peptides which may be used to test for the presence of antibodies to | 04-30-2009 |
20090232797 | PLASMODIUM MALARIAE AND PLASMODIUM OVALE GENES AND USES THEREOF - The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the | 09-17-2009 |
20100247576 | NUCLEOTIDE AND AMINO ACID SEQUENCES ENCODING AN EXPORTED PROTEIN 1 DERIVED FROM PLASMODIUM VIVAX AND USES THEREOF - The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of | 09-30-2010 |
20100279432 | INDIRECTLY LABELLED ASSAY CONJUGATES AND METHODS OF PREPARING AND USING SAME - Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided. | 11-04-2010 |
20110311572 | NUCLEOTIDE AND AMINO ACID SEQUENCES ENCODING AN EXPORTED PROTEIN 1 DERIVED FROM PLASMODIUM VIVAX AND USES THEREOF - The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of | 12-22-2011 |
20120202295 | MATERIALS AND METHODS FOR ASSAY OF ANTI-HEPATITIS C VIRUS (HCV) ANTIBODIES - A polypeptide comprising the contiguous amino acids 1-198 of SEQ ID NO: 2; a polypeptide, which comprises a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO: 2, an epitope that is immunoreactive with an antibody that specifically binds to the core protein of hepatitis C virus (HCV), and an epitope that is immunoreactive with an antibody that specifically binds to the NS4 region of HCV; a nucleic acid encoding such a polypeptide; a host cell comprising such a nucleic acid; an immunodiagnostic reagent comprising such a polypeptide; a kit comprising such an immunodiagnostic reagent; and a method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample. | 08-09-2012 |
20120329176 | INDIRECTLY LABELLED ASSAY CONJUGATES AND METHODS OF PREPARING AND USING SAME - Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided. | 12-27-2012 |
Patent application number | Description | Published |
20110097797 | Modular Functional Peptides for the Intracellular Delivery of Nanoparticles - Described are peptides for delivery of a nanoparticle to the cytosol, the peptide comprising: (a) a nanoparticle association domain; (b) a proline-rich spacer domain; (c) an uptake domain; and (d) a vesicle escape domain comprising a non-hydrolyzable lipid moiety, wherein the spacer domain is between the nanoparticle association domain and the uptake and vesicle escape domains, and wherein the peptide, when attached to an extracellular nanoparticle, is effective to induce uptake of the nanoparticle by a cell and delivery of the nanoparticle to the cytosol of the cell. Also described are methods of delivery of a nanoparticle to the cytosol of a cell, the method comprising providing to a cell a nanoparticle attached to such a peptide. Exemplary nanoparticles include quantum dots. | 04-28-2011 |
20130129627 | Delivery of Nanoparticles to Neurons - A peptide attached to a nanoparticles (such as quantum dots) selectively directs the nanoparticles to neurons in a tissue or organism. | 05-23-2013 |
20130130296 | Modular Functional Peptides for Delivery of Nanoparticles - A peptide directs nanoparticles (such as quantum dots) to the plasma membrane of mammalian cells. A method of delivery of a nanoparticle to a plasma membrane of a cell includes providing to the cell a nanoparticle attached to a peptide configured to direct the nanoparticle the plasma membrane, and allowing the cell to take up the nanoparticle. The nanoparticle can be a FRET donor to an organic dye. | 05-23-2013 |
20130158244 | Modular Functional Peptides for the Intracellular Delivery of Nanoparticles - Described are nucleic acids encoding a polypeptide for delivery of a nanoparticle to the cytosol, the peptide comprising: (a) a nanoparticle association domain, (b) a spacer domain, (c) an uptake domain, and (d) a vesicle escape domain, wherein the domains (a) through (d) appear in the same order as listed above, and wherein the peptide, upon addition of a non-hydrolyzable lipophilic moiety to the vesicle escape domain and binding to a nanoparticle, is effective to induce uptake of a nanoparticle by a cell and delivery of the nanoparticle to the cytosol of the cell. Also described are methods of delivery of a nanoparticle to the cytosol of a cell, the method comprising providing to a cell a nanoparticle attached to such a peptide. Exemplary nanoparticles include quantum dots. | 06-20-2013 |